The Use of Omics Sciences in Allergic Diseases From Bench to Bedside: An EAACI Position Paper

Omics have revolutionized our understanding of allergic diseases, with increasingly more studies adopting techniques like genomics, proteomics, and metabolomics over the years. Integrating high‐dimensional omics data with clinical features can enable more precise disease classification and biomarker identification, leading to improved disease management and the development of novel therapies. However, translating these discoveries into clinical practice remains a challenge. In this European Academy of Allergy and Clinical Immunology (EAACI) Position Paper, the Task Force (TF) “The Use of Omics Sciences in Asthma and Allergy Clinical Practice” performed a broad review of recent papers where omics technologies were used in the context of clinical studies and provided a summary of relevant findings in the field of asthma, atopic dermatitis, allergic rhinitis, food allergy and drug hypersensitivity reactions. Particular attention was dedicated to studies investigating overlapping diseases/co‐morbidities, revealing unique and shared signatures that could guide future therapeutic and research efforts. Furthermore, current hurdles in translating findings from bench to bedside were explained, and possible solutions were offered. With this position paper, the TF aims to assist researchers and clinicians by providing an overview of the investigations performed to date, highlighting gaps in research, limitations, and avenues for further exploration in clinical practice.